What Made Thermo Fisher Scientific (TMO) a Solid Performer in Q3?

2 weeks ago 8

Soumya Eswaran

Thu, December 4, 2025 astatine 8:26 AM CST 3 min read

Harding Loevner, an plus absorption company, released its “Global Equity Strategy” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The money returned 2.62% gross (2.52% net) successful the 3rd 4th of 2025, compared to a 7.74% instrumentality for the MSCI All Country World Index and 7.36% summation for the MSCI World Index. YTD, the strategy roseate 10.61% (net) compared to 18.86% and 17.83% for the indexes. The steadfast highlighted successful the missive that the past six months represented 1 of the strongest momentum phases successful implicit 70 years. Since the opening of the year, high-momentum stocks person outperformed low-momentum stocks by a singular 45 percent points, with overmuch of the maturation driven by advancements successful AI. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Harding Loevner Global Equity Strategy highlighted stocks specified arsenic Thermo Fisher Scientific Inc. (NYSE:TMO). Thermo Fisher Scientific Inc. (NYSE:TMO) offers beingness sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services. The one-month instrumentality of Thermo Fisher Scientific Inc. (NYSE:TMO) was 2.56%, and its shares gained 11.44% of their worth implicit the past 52 weeks. On December 03, 2025, Thermo Fisher Scientific Inc. (NYSE:TMO) banal closed astatine $580.45 per share, with a marketplace capitalization of $218.08 billion.

Harding Loevner Global Equity Strategy stated the pursuing regarding Thermo Fisher Scientific Inc. (NYSE:TMO) successful its 3rd 4th 2025 capitalist letter:

"While the marketplace has mistaken the Health Care sector's income declines from pandemic-inflated levels arsenic grounds of structural decline, determination are present signs that a betterment is underway-in companies' income and successful their stock prices. Operating fundamentals successful cardinal extremity markets are stabilizing from pandemic dislocations. Hospital finances improved successful aboriginal 2025 from the twelvemonth earlier arsenic volumes normalized and gross maturation outpaced expenses, though the betterment successful the US could inactive beryllium rocky owed to argumentation uncertainty. Medical exertion and services companies whose products are tied to aesculapian procedures are apt to spot amended pricing powerfulness and a much favorable income premix if diligent utilization of the health-care strategy continues to stabilize. Life sciences tools should besides payment from healing superior budgets. Finally, the superior rhythm is turning much supportive. Dealmaking has returned to the assemblage amid expanding clarity connected caller US cause pricing implementation timelines. Thermo Fisher Scientific Inc. (NYSE:TMO), the world's largest supplier of life-sciences tools, offers an aboriginal motion of a shift: though its results for the 2nd 4th (reported successful July) lone modestly exceeded expectations, absorption forecast 3-6% integrated gross maturation adjacent year, and 7% beyond 2027-an outlook that was amended than investors feared. The banal surged successful response, and it was a coagulated performer for the quarter."